| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | -100.00% |
| Net Income | -16,370 | -17,980 | -18,090 | -20,400 | -16,670 |
| Net Income Growth | +8.95% | +0.61% | +11.32% | -22.38% | +3.36% |
Werewolf Therapeutics Inc (HOWL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31